Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?

Current Opinion in Psychiatry

Volumn 27, Issue 2, 2014, Pages 128-137

  Panza, Francesco ^a   Logroscino, Giancarlo ^a   Imbimbo, Bruno P ^b   Solfrizzi, Vincenzo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Research and Development Department   (Italy)

Author keywords

active immunotherapy; gantenerumab; monoclonal antibody; passive immunotherapy; solanezumab

Indexed keywords

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY;

EID: 84894033757     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0000000000000041     Document Type: Review

References (93)

1. Thies W, Bleiler L, Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimers Dement 2013; 9:208-245.
2. Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010; 9:702-716.
3. Panza F, Solfrizzi V, Frisardi V, et al. Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging 2009; 26:537-555.
4. Newell KL, Hyman BT, Growdon JH, Hedley-Whyte ET. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuro-pathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol 1999; 58:1147-1155.
5. Walter J, Kaether C, Steiner H, Haass C. The cell biology of Alzheimer's disease: uncovering the secrets of secretases. Curr Opin Neurobiol 2001; 11:585-590.
6. Seubert P, Vigo-Pelfry C, Esch F, et al. Isolation and quantification of soluble Alzheimer's p-peptide from biological fluids. Nature 1996; 359: 325-327.
7. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of Ap42(43) and Ap40 in senile plaques with specific Ap monoclonals: evidence that the initially deposited species is Ap42(43). Neuron 1993; 13:45-53.
8. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991; 12:383-388.
9. Armstrong RA. The pathogenesis of Alzheimer's disease: a reevaluation of the 'Amyloid Cascade Hypothesis'. Int J Alzheimers Dis 2011; 2011:630865. doi:10.4061/2011/630865.
10. Giasson Bl, Lee VMY, Trojanowski JQ. Interactions of amyloidogenic proteins. Neuromolecular Med 2003; 4:49-58.
11. Smith MA, Siedlak SL, Richey PL, et al. Tau protein directly interacts with the amyloid p-protein precursor: implications for Alzheimer's disease. Nat Med 1995; 1:365-369.
12. Oyama F, Shimada H, Oyama R, et al. p-amyloid protein precursor and T mRNA levels versus p-amyloid plaque and neurofibrillary tangles in the aged human brain. J Neurochem 1993; 60:1658-1664.
13. Terry RD. Alzheimer's disease and the aging brain. J Geriatr Psychiatry Neurol 2006; 19:125-128.
14. McDonald JM, Savva GM, Brayne C, et al., Medical Research Council Cognitive Function and Ageing Study. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 2010; 133:1328-1341.
15. Shankar GM, Li S, Mehta TH, et al. Amyloid-p protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14:837-842.
16. Moreth J, Mavoungou C, Schindowski K. Passive antiamyloid immunotherapy in Alzheimer's disease: what are the most promising targets? Immun Ageing 2013; 10:18.
17. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-p protein assembly in the brain impairs memory. Nature 2006; 440:352-357.
18. Koffie RM, Meyer-Luehmann M, Hashimoto T, et al. Oligomeric amyloid p associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 2009; 106:4012-4017.
19. Bateman RJ, Xiong C, Benzinger TL, et al., Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367:795-804.
20. Villemagne VL, Burnham S, Bourgeat P, et al., Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid p deposition, neurodegenera-tion, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013; 12:357-367.
21. Panza F, Frisardi V, Solfrizzi V, et al. Immunotherapy for Alzheimer's disease: from antip-amyloid to tau-based immunization strategies. Immunotherapy 2012;4:213-238.
22. Li Y, Liu Y, Wang Z, Jiang Y. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end? Expert Opin Biol Ther 2013; 13:1515-1522.
23. Sarazin M, Dorothee G, de Souza LC, Aucouturier P. Immunotherapy in Alzheimer's disease: do we have all the pieces of the puzzle? Biol Psychiatry 2013; 74:329-332.
24. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177.
25. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002; 3:824-828.
26. Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immuno-genicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005; 64:94-101.
27. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61:46-54.
28. Ferrer I, Boada Rovira M, Sanchez Guerra ML, et al. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004; 14:11-20.
29. Vellas B, Black R, Thai U, et al., AN1792 (QS-21)-251 Study Team. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009; 6:144-151.
30. Masliah E, Hansen L, Adame A, et al. Ab vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005; 64:129-131.
31. Bombois S, Maurage CA, Gompel M, et al. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch Neurol 2007; 64:583-587.
32. Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64:1553-1562.
33. Hock C, Konietzko U, Streffer JR, et al. Antibodies against b-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38:547-554.
34. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Ab42 fibrils. Science 2001; 293:1491-1495.
35. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003; 62:1087-1095.
36. Oddo S, Billings L, Kesslak JP, et al. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004;43:321-332.
37. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Ab42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled Phase I trial. Lancet 2008; 372:216-223.
38. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010; 6:108-119.
39. Sigurdsson EM, Scholtzova H, Mehta PD, etal. Immunization with a nontoxic/nonfibrillar amyloid-p homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 2001; 159:439-447.
40. Movsesyan N, Ghochikyan A, Mkrtichyan M, etal. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine: a novel immunothera-peutic strategy. PLoS One 2008; 3:e2124.
41. Movsesyan N, Mkrtichyan M, Petrushina I, et al. DNA epitope vaccine containing complement component C3d enhances antiamyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype. J Neuroimmunol 2008; 205:57-63.
42. Li Y, Ma Y, Zong LX, et al. Intranasal inoculation with an adenovirus vaccine encoding ten repeats of Ap3-10 reduces AD-like pathology and cognitive impairment in Tg-APPswe/PSEN1dE9 mice. J Neuroimmunol 2012; 249: 16-26.
43. Frenkel D, Dewachter I, Van Leuven F, Solomon B. Reduction of p-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization. Vaccine 2003; 21:1060-1065.
44. Qu B, Rosenberg RN, Li L, et al. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol 2004; 61:1859-1864.
45. Okura Y, Miyakoshi A, Kohyama K, etal. Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. Proc Natl Acad Sci USA 2006; 103:9619-9624.
46. Bach P, Tschape JA, Kopietz F, et al. Vaccination with Ap-displaying virus-like particles reduces soluble and insoluble cerebral Ap and lowers plaque burden in APP transgenic mice. J Immunol 2008; 182:7613-7624.
47. Matsumoto Y, Niimi N, Kohyama K. Development of a new DNA vaccine for Alzheimer disease targeting a wide range of Ap species and amyloidogenic peptides. PLoS One 2013; 8:e75203.
48. Agadjanyan MG, Ghochikyan A, Petrushina I, et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from p-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005; 174:1580-1586.
49. Petrushina I, Ghochikyan A, Mktrichyan M, et al. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Ap species in amyloid precursor protein transgenic mice. J Neurosci 2007; 27:12721-12731.
50. Bowers WJ, Mastrangelo MA, Stanley HA, et al. HSV amplicon-mediated Ap vaccination in Tg2576 mice: differential antigen-specific immune responses. Neurobiol Aging 2005; 26:393-407.
51. Santuccione AC, Merlini M, Shetty A, et al. Active vaccination with ankyrin G reduces p-amyloid pathology in APP transgenic mice. Mol Psychiatry 2013; 18:358-368.
52. Davtyan H, Ghochikyan A, Petrushina I, etal. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's isease: prelude to a clinical trial. J Neurosci 2013; 33:4923-4934.
53. Wiessner C, Wiederhold KH, Tissot AC, et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 2011; 31:9323-9331.
54. Winblad B, Andreasen N, Minthon L, etal. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-inhuman study. Lancet Neurol 2012; 11:597-604.
55. Ryan JM, Grundman M. Antiamyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing. J Alzheimers Dis 2009; 17:243.
56. Schneeberger A, Mandler M, Otawa O, et al. Development of AFFITOPE vaccines for Alzheimer's disease (AD): from concept to clinical testing. J Nutr Health Aging 2009; 13:264-267.
57. Lambracht-Washington D, Rosenberg RN. Advances in the development of vaccines for Alzheimer's disease. Discov Med 2013; 15:319-326.
58. Lemere CA. Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener 2013; 8:36.
59. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid p-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6:916-919.
60. Morgan D. Mechanisms of A beta plaque clearance following passive Abeta immunization. Neurodegener Dis 2005; 2:261-266.
61. Panza F, Frisardi V, Imbimbo BP, et al. Antip-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab. Curr Alzheimer Res 2011; 8:808-817.
62. Imbimbo BP, Ottonello S, Frisardi V, et al. Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. Expert Rev Clin Immunol 2012; 8:135-149.
63. Tayeb HO, Murray ED, Price BH, Tarazi Fl. Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive? Expert Opin Biol Ther 2013; 13:1075-1084.
64. Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011; 7:367-385.
65. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009; 73:2061-2070.
66. Rinne JO, Brooks DJ, Rossor MN, etal. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010; 9:363-372.
67. Blennow K, Zetterberg H, Rinne JO, et al. AAB-001201/202 Investigators. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 2012; 69:1002-1010.
68. Seubert P, Barbour R, Khan K, etal. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener Dis 2008; 5:65-71.
69. Farlow M, Arnold SE, van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 2012; 8:261-271.
70. Siemers ER, Friedrich S, Dean RA, et al. Safety and changes in plasma and cerebrospinal fluid amyloid-beta after a single administration of an amyloid-beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010; 33:67-73.
71. Miller G. News focus: stopping Alzheimer's before it starts. Science 2012; 337:790-792.
72. Dubois B, Feldman HH, Jacova C, etal. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6:734-746.
73. Dubois B, Feldman HH, Jacova C, etal. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010; 9:1118-1127.
74. Bohrmann B, Baumann K, Benz J, etal. Gantenerumab: a novel human anti-Ap antibody demonstrates sustained cerebral amyloid-p binding and elicits cell-mediated removal of human amyloid-p. J Alzheimers Dis 2012; 28:49-69.
75. Ostrowitzki S, Deptula D, Thurfjell L, etal. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012; 69:198-207.
76. Delrieu J, Ousset PJ, Vellas B. Gantenerumab for the treatment of Alzheimer's disease. Expert Opin Biol Ther 2012; 12:1077-1086.
77. Morris JC, Aisen PS, Bateman RJ, et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig 2012; 2:975-984.
78. Freeman GB, Lin JC, Pons J, Raha NM. 39-week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period. J Alzheimers Dis 2012; 28:531-541.
79. Burstein AH, Zhao Q, Ross J, et al. Safety and pharmacology of ponezumab (PF-04360365) after a single 10-min intravenous infusion in subjects with mild to moderate Alzheimer disease. Clin Neuropharmacol 2013; 36:8-13.
80. Landen JW, Zhao Q, Cohen S, et al. Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mi Id-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study. Clin Neuropharmacol 2013; 36:14-23.
81. Adolfsson O, Pihlgren M, Toni N, etal. An effector-reduced antip-amyloid (Ap) antibody with unique Ap binding properties promotes neuroprotection and glial engulfment of Ap. J Neurosci 2012; 32:9677-9689.
82. Garber K. Genentech's Alzheimer's antibody trial to study disease prevention. Nat Biotechnol 2012; 30:731-732.
83. Lemere CA, Lopera F, Kosik KS, et al. The E280A presenilin 1 Alzheimer mutation produces increased Ap42 deposition and severe cerebellar pathology. Nat Med 1996; 2:1146-1150.
84. Lopera F, Ardilla A, Martinez A, etal. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 1997; 277:793-799.
85. Pul R, Dodel R, Stangel M. Antibody-based therapy in Alzheimer's disease. Expert Opin Biol Ther 2011; 11:343-357.
86. Loeffler DA. Intravenous immunoglobulin and Alzheimer's disease: what now? J Neuroinflammation 2013; 10:70.
87. Dodel R, Rominger A, Bartenstein P, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2013; 12:233-243.
88. Lee EB, Leng LZ, Zhang B, et al. Targeting amyloid-b peptide (Ap) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Ap precursor protein (APP) transgenic mice. J Biol Chem 2006; 281:4292-4299.
89. Lambert MP, Velasco PT, Chang L, et al. Monoclonal antibodies that target pathological assemblies of Ap. J Neurochem 2007; 100:23-35.
90. Frost JL, Liu B, Kleinschmidt M, et al. Passive immunization against pyroglutamate-3 amyloid-p reduces plaque burden in Alzheimer's-like transgenic mice: a pilot study. Neurodegenerative Dis 2012; 10:265-270.
91. Kim J, Eltorai AE, Jiang H, et al. AntiapoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Ap amyloidosis. J Exp Med 2012; 209:2149-2156.
92. Demattos RB, Lu J, Tang Y, et al. A plaque-specific antibody clears existing p-amyloid plaques in Alzheimer's disease mice. Neuron 2012; 76:908-920.
93. Morales-Corraliza J, Schmidt SD, Mazzella MJ, et al. Immunization targeting a minor plaque constituent clears p-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model. Neurobiol Aging 2013; 34:137-145.